Ravn Bo, Prowle John R, Mårtensson Johan, Martling Claes-Roland, Bell Max
1Section of Anesthesia and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. 2Centre for Translational Medicine & Therapeutics, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom. 3Adult Critical Care Unit, Department of Renal Medicine, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom. 4Department of Intensive Care, Austin Hospital, Heidelberg, Melbourne, VIC, Australia.
Crit Care Med. 2017 Sep;45(9):e932-e940. doi: 10.1097/CCM.0000000000002537.
Renal outcomes after critical illness are seldom assessed despite strong correlation between chronic kidney disease and survival. Outside hospital, renal dysfunction is more strongly associated with mortality when assessed by serum cystatin C than by creatinine. The relationship between creatinine and longer term mortality might be particularly weak in survivors of critical illness.
Retrospective observational cohort study.
In 3,077 adult ICU survivors, we compared ICU discharge cystatin C and creatinine and their association with 1-year mortality. Exclusions were death within 72 hours of ICU discharge, ICU stay less than 24 hours, and end-stage renal disease.
None.
During ICU admission, serum cystatin C and creatinine diverged, so that by ICU discharge, almost twice as many patients had glomerular filtration rate less than 60 mL/min/1.73 m when estimated from cystatin C compared with glomerular filtration rate estimated from creatinine, 44% versus 26%. In 743 patients without acute kidney injury, where ICU discharge renal function should reflect ongoing baseline, discharge glomerular filtration rate estimated from creatinine consistently overestimated follow-up glomerular filtration rate estimated from creatinine, whereas ICU discharge glomerular filtration rate estimated from cystatin C well matched follow-up chronic kidney disease status. By 1 year, 535 (17.4%) had died. In survival analysis adjusted for age, sex, and comorbidity, cystatin C was near-linearly associated with increased mortality, hazard ratio equals to 1.78 (95% CI, 1.46-2.18), 75th versus 25th centile. Conversely, creatinine demonstrated a J-shaped relationship with mortality, so that in the majority of patients, there was no significant association with survival, hazard ratio equals to 1.03 (0.87-1.2), 75th versus 25th centile. After adjustment for both creatinine and cystatin C levels, higher discharge creatinine was then associated with lower long-term mortality.
In contrast to creatinine, cystatin C consistently associated with long-term mortality, identifying patients at both high and low risk, and better correlated with follow-up renal function. Conversely, lower creatinine relative to cystatin C appeared to confer adverse prognosis, confounding creatinine interpretation in isolation. Cystatin C warrants further investigation as a more meaningful measure of renal function after critical illness.
尽管慢性肾脏病与生存率之间存在密切关联,但危重症后的肾脏转归很少得到评估。在院外,通过血清胱抑素C评估的肾功能不全与死亡率的相关性比通过肌酐评估的更强。在危重症幸存者中,肌酐与长期死亡率之间的关系可能特别弱。
回顾性观察队列研究。
在3077名成年ICU幸存者中,我们比较了ICU出院时的胱抑素C和肌酐水平及其与1年死亡率的关联。排除标准为ICU出院后72小时内死亡、ICU住院时间少于24小时以及终末期肾病。
无。
在ICU住院期间,血清胱抑素C和肌酐出现差异,以至于到ICU出院时,根据胱抑素C估算的肾小球滤过率低于60 mL/min/1.73 m²的患者数量几乎是根据肌酐估算的两倍,分别为44%和26%。在743例无急性肾损伤的患者中,ICU出院时的肾功能应反映持续的基线水平,根据肌酐估算的出院肾小球滤过率持续高估了根据肌酐估算的随访肾小球滤过率,而根据胱抑素C估算的ICU出院肾小球滤过率与随访时的慢性肾脏病状态匹配良好。到1年时,535例(17.4%)患者死亡。在对年龄、性别和合并症进行校正的生存分析中,胱抑素C与死亡率增加呈近似线性关联,风险比为1.78(95%CI,1.46 - 2.18),第75百分位数与第25百分位数相比。相反,肌酐与死亡率呈J形关系,因此在大多数患者中,与生存率无显著关联,风险比为1.03(0.87 - 1.2),第75百分位数与第25百分位数相比。在对肌酐和胱抑素C水平进行校正后,较高的出院肌酐水平与较低的长期死亡率相关。
与肌酐不同,胱抑素C始终与长期死亡率相关,可识别高危和低危患者,且与随访肾功能的相关性更好。相反,相对于胱抑素C而言较低的肌酐水平似乎预示着不良预后,这使得单独解读肌酐结果时产生混淆。胱抑素C作为危重症后更有意义的肾功能指标值得进一步研究。